Boston Faces Identity Crisis Amid Trump’s Cuts to University and Research Fundingnews2025-04-06T09:01:05+00:00April 6th, 2025|The New York Times|
FDA Approves Journavx Drug to Treat Pain Without Addiction Risknews2025-01-31T00:12:17+00:00January 31st, 2025|The New York Times|
F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editingnews2023-12-09T02:22:13+00:00December 9th, 2023|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approvalnews2023-11-16T22:23:56+00:00November 16th, 2023|The New York Times|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
‘Miracle’ Cystic Fibrosis Drug Kept Out of Reach in Developing Countriesnews2023-02-07T21:15:45+00:00February 7th, 2023|The New York Times|
La larga espera por la cura de la diabetesnews2022-08-17T07:00:08+00:00August 17th, 2022|The New York Times|
The Long, Long Wait for a Diabetes Curenews2022-08-09T07:00:10+00:00August 9th, 2022|The New York Times|
